Results 251 to 260 of about 97,922 (342)

MiR-124 and MiR-155 as Therapeutic Targets in Microglia-Mediated Inflammation in Multiple Sclerosis. [PDF]

Cell Mol Neurobiol
Asl ER, Hosseini SE, Tahmasebi F, Bolandi N, Barati S.   +4 more
europepmc   +1 more source

MYCN amplification defines an aggressive phenotype in IDH‐mutant gliomas

The Journal of Pathology: Clinical Research, Volume 11, Issue 5, September 2025.
Abstract In alignment with the latest WHO classification system, which underscores the integration of molecular alterations in glioma diagnosis and grading, this study investigates the prognostic significance of MYCN amplification in IDH‐mutant gliomas, a relationship that remains poorly characterized despite its established association with adverse ...
Xujun Xie, Qin Yan, Fang Wang, Jiabin Lu, Yuandong Zhang, Shaoyan Xi   +5 more
wiley   +1 more source

Aggressive intracranial meningioma associated with multiple sclerosis: A case report and literature review. [PDF]

Med Int (Lond)
Patel T, Fatima I, Chandrasekaran SH, Rameshkumar SS, Makky H, Ali S, Suvra Patra S, Qamar Y.   +7 more
europepmc   +1 more source

Neutralization of the Chemokine CXCL10 Reduces Inflammatory Cell Invasion and Demyelination and Improves Neurological Function in a Viral Model of Multiple Sclerosis

, 2001
Michael T. Liu, Hans S. Keirstead, Thomas E. Lane   +2 more
openalex   +1 more source

Randomized, Double‐Blind, Placebo‐Controlled, Multiple‐Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis

Annals of Neurology, Volume 98, Issue 3, Page 590-602, September 2025.
Objective Elezanumab is a monoclonal antibody that binds repulsive guidance molecule a (RGMa), an inhibitor of central nervous system regeneration after inflammation or injury. The aim was to assess the safety and efficacy of elezanumab in relapsing and progressive forms of multiple sclerosis (MS).
Bruce A.C. Cree, Mark S. Freedman, Michael Gold, Kimberly Pfleeger, Brittany Schwefel, Annette Wundes, Adam Ziemann   +6 more
wiley   +1 more source

Synergistic Effects of Olfactory Ecto-Mesenchymal Stem Cell Supernatant and Ellagic Acid on Demyelination and Glial Modulation in a Chronic Multiple Sclerosis Model. [PDF]

Cell Mol Neurobiol
Tahmasebi F, Asl ER, Faghihi F, Bolandi N, Barati S.   +4 more
europepmc   +1 more source

Longitudinal Analysis of Neuroradiological Biomarkers for Fragile X‐Associated Tremor/Ataxia Syndrome and Implications for Clinical Trials

Annals of Neurology, Volume 98, Issue 3, Page 471-481, September 2025.
Objective The objective of this study was to show the capacity of structural brain magnetic resonance imaging (MRI) measures to serve as monitoring biomarkers for Fragile X‐Associated Tremor/Ataxia Syndrome (FXTAS). Methods From 2 longitudinal studies of male FMR1 premutation carriers, 2 brain MRI scans were selected from each participant, collected ...
David Hessl, Jun Yi Wang, Glenda Espinal, Ellery Santos, Flora Tassone, Randi J. Hagerman, Susan M. Rivera   +6 more
wiley   +1 more source

PRES or ODS: An atypical presentation of osmotic demyelination syndrome? [PDF]

Radiol Case Rep
Wiley J, Colantonio M, Hollingsworth N, Shakesprere J.   +3 more
europepmc   +1 more source

Exploring the Causal Links Between 338 Cerebrospinal Fluid Metabolites and Parkinson's Disease

Brain and Behavior, Volume 15, Issue 9, September 2025.
This Mendelian randomization study systematically screened 338 cerebrospinal fluid metabolites and identified several with potential causal effects on Parkinson's disease, offering new insights into disease pathogenesis. ABSTRACT Background Parkinson's disease (PD) is a progressive neurodegenerative condition characterized by motor impairments and ...
Houwen Zhang, Chunrong Li, Jialin Yu, Yu Liang, You Wu, Fangzheng Cao   +5 more
wiley   +1 more source

Neuroprotection unveiled: melatonin mitigates apoptotic pathways in traumatic brain injury. [PDF]

Front Neurol
Gunara SO, Akgun MY, Seker U, Ucar EA, Ates O, Basar I.   +5 more
europepmc   +1 more source